Novartis AG ADR (NVS)vsPsyence Biomedical Ltd. Common Shares (PBM)
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
PBM
Psyence Biomedical Ltd. Common Shares
$3.69
-6.58%
HEALTHCARE · Cap: $7.64M
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
NVS
Hold49
out of 100
Grade: D+
PBM
Avoid26
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Intrinsic value data unavailable for PBM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PBM
The strongest argument for PBM centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : PBM
The primary concerns for PBM are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
NVS profiles as a declining stock while PBM is a value play — different risk/reward profiles.
PBM carries more volatility with a beta of 1.65 — expect wider price swings.
PBM is growing revenue faster at 0.0% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (49/100 vs 26/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Psyence Biomedical Ltd. Common Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Psyence Biomedical Ltd. (PBM) is a cutting-edge biotechnology firm focused on harnessing the therapeutic potential of psychedelic compounds to transform mental health and wellness treatments. Through its vertically integrated model, the company excels in the cultivation, formulation, and clinical research of psilocybin and other psychedelics, aiming to develop novel therapies that meet the pressing needs of patients. With a robust intellectual property portfolio and a promising clinical pipeline, Psyence is strategically positioned to leverage the increasing acceptance of psychedelics in the healthcare landscape, addressing urgent mental health challenges with innovative and effective solutions.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?